FierceBiotech |
Merck finally ditches osteoporosis drug odanacatib after stroke risk FierceBiotech Two years ago the Big Pharma announced it was to delay a filing with the FDA after Phase III results showed that while the drug could reduce fractures, it also increased the risk of atrial fibrillation and stroke. It had hoped for a 2015 U.S. approval … Merck Halts Development of ... |
4
SEP
SEP
0